All In Biotech

Free tool

FAERS Monitor: Avmapki Fakzynja CO-Pack (Copackaged)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219616 or its brand name (Avmapki Fakzynja CO-Pack (Copackaged), Avutometinib Potassium, Defactinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,125

Serious

175

16% of reports

Hospitalization

123

Death reported

37

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use191
  • fatigue168
  • nausea156
  • diarrhoea119
  • rash116
  • product dose omission issue99
  • vomiting79
  • vision blurred67
  • peripheral swelling66
  • acne57
  • pruritus54
  • dry skin46
  • dizziness42
  • constipation40
  • disease progression38

Reports by year received

View as table
YearReports
2025288
2026837

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acneSignal5714.110.9681
vision blurredSignal679.17.2480
peripheral swellingSignal668.06.3401
dry skinSignal466.44.9207
product dose omission issueSignal996.35.2442
disease progressionSignal386.04.4154
rashSignal1165.04.2372
off label useSignal1914.13.6460
fatigueSignal1684.03.5395
nauseaSignal1563.73.2314
diarrhoeaSignal1193.42.9211
constipationSignal403.42.567
vomitingSignal793.12.5116
pruritusSignal542.62.054
dizziness421.61.28

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.